Trial Profile
Study combining antimuscarinic or mirabegron in overactive bladder patients treated with 100 U onabotulinumtoxinA
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2018
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Solifenacin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 27 Sep 2018 New trial record
- 31 Aug 2018 Primary endpoint has been met.
- 31 Aug 2018 Results presented at the 48th Annual Meeting of the International Continence Society